Menu Search
Equities

Biovica International AB

9II:FRA

Biovica International AB

Actions
  • Price (EUR)0.1256
  • Today's Change0.000 / 0.32%
  • Shares traded1.00k
  • 1 Year change-35.77%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 08:16 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.

  • Revenue in SEK (TTM)7.25m
  • Net income in SEK-115.45m
  • Incorporated2008
  • Employees27.00
  • Location
    Biovica International ABDag Hammarskjolds vag 54BUppsala Science ParkUPPSALA 752 37SwedenSWE
  • Phone+46 184444830
  • Fax+46 18572428
  • Websitehttps://biovica.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.